title: Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901.
abstract: The development of efficient immunotherapies requires strong rationalization. We have recently implemented a large analysis of biomarkers in two studies involving the multi-peptide vaccine IMA901 and advanced renal cell cancer patients. Our findings demonstrate that the breadth of immune responses was associated with clinical benefits and that single-dose cyclophosphamide reduced the amount of regulatory T cells and was associated with prolonged survival after vaccination.
authors.affiliation: Immatics Biotechnologies GmbH; Tuebingen, Germany.
authors.forename: Steffen
authors.initials: S
authors.lastname: Walter
authors.forename: Toni
authors.initials: T
authors.lastname: Weinschenk
authors.forename: Carsten
authors.initials: C
authors.lastname: Reinhardt
authors.forename: Harpreet
authors.initials: H
authors.lastname: Singh-Jasuja
keywords: T cells; biomarkers; cancer; immunomonitoring; immunotherapy; low-dose cyclophosphamide; peptides; randomized clinical trial; regulatory T cells; renal cell cancer; vaccine